Loading...

We've got a brand new version of Simply Wall St! Try it out

Race Oncology

ASX:RAC
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RAC
ASX
A$6M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The last earnings update was 171 days ago. More info.


Add to Portfolio Compare Print
  • Race Oncology has significant price volatility in the past 3 months.
RAC Share Price and Events
7 Day Returns
-1.5%
ASX:RAC
2.9%
AU Biotechs
-2.6%
AU Market
1 Year Returns
-53.6%
ASX:RAC
6.6%
AU Biotechs
-0.7%
AU Market
RAC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Race Oncology (RAC) -1.5% 30% -8.5% -53.6% -69% -
AU Biotechs 2.9% 1.3% 9.7% 6.6% 107.4% 185.5%
AU Market -2.6% -4.1% 0.5% -0.7% 13% 5.9%
1 Year Return vs Industry and Market
  • RAC underperformed the Biotechs industry which returned 6.6% over the past year.
  • RAC underperformed the Market in Australia which returned -0.7% over the past year.
Price Volatility
RAC
Industry
5yr Volatility vs Market

Value

 Is Race Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Race Oncology. This is due to cash flow or dividend data being unavailable. The share price is A$0.065.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Race Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Race Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:RAC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.07
ASX:RAC Share Price ** ASX (2019-08-13) in AUD A$0.07
Global Biotechs Industry PE Ratio Median Figure of 79 Publicly-Listed Biotechs Companies 21.41x
Australia Market PE Ratio Median Figure of 538 Publicly-Listed Companies 15.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Race Oncology.

ASX:RAC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:RAC Share Price ÷ EPS (both in AUD)

= 0.07 ÷ -0.07

-1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Race Oncology is loss making, we can't compare its value to the Global Biotechs industry average.
  • Race Oncology is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Race Oncology's expected growth come at a high price?
Raw Data
ASX:RAC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 58 Publicly-Listed Biotechs Companies 0.95x
Australia Market PEG Ratio Median Figure of 352 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Race Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Race Oncology's assets?
Raw Data
ASX:RAC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.08
ASX:RAC Share Price * ASX (2019-08-13) in AUD A$0.07
Australia Biotechs Industry PB Ratio Median Figure of 42 Publicly-Listed Biotechs Companies 2.68x
Australia Market PB Ratio Median Figure of 1,687 Publicly-Listed Companies 1.67x
ASX:RAC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:RAC Share Price ÷ Book Value per Share (both in AUD)

= 0.07 ÷ 0.08

0.83x

* Primary Listing of Race Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Race Oncology is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Race Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Race Oncology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Race Oncology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Race Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.3%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Race Oncology expected to grow at an attractive rate?
  • Unable to compare Race Oncology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Race Oncology's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Race Oncology's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:RAC Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 11.3%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 9.1%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.9%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:RAC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:RAC Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:RAC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -3 -5
2018-09-30 0 -3 -6
2018-06-30 0 -4 -6
2018-03-31 0 -4 -6
2017-12-31 0 -4 -6
2017-09-30 0 -3 -5
2017-06-30 -2 -4
2017-03-31 -2 -3
2016-12-31 -1 -2
2016-09-30 -1 -1
2016-06-30 0 0
2016-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Race Oncology is high growth as no earnings estimate data is available.
  • Unable to determine if Race Oncology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:RAC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Race Oncology Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RAC Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:RAC Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.07
2018-09-30 -0.08
2018-06-30 -0.09
2018-03-31 -0.09
2017-12-31 -0.10
2017-09-30 -0.09
2017-06-30 -0.08
2017-03-31 -0.07
2016-12-31 -0.07
2016-09-30 -0.06
2016-06-30 -0.03
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Race Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Race Oncology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Race Oncology's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Race Oncology's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Race Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Race Oncology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Race Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Race Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Race Oncology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Race Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Race Oncology's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Race Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Race Oncology Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RAC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.23 -4.84 3.32 1.54
2018-09-30 0.20 -5.58 3.82 1.64
2018-06-30 0.17 -6.31 4.33 1.75
2018-03-31 0.17 -5.94 3.86 1.31
2017-12-31 0.17 -5.58 3.33 1.37
2017-09-30 0.09 -4.88 2.96 1.29
2017-06-30 -4.17 2.58 1.21
2017-03-31 -3.19 2.17 0.85
2016-12-31 -2.20 1.75 0.50
2016-09-30 -1.26 1.09 0.25
2016-06-30 -0.32 0.42
2016-03-31 -0.30 0.31
2015-12-31 -0.28 0.20
2015-09-30 -0.18 0.14
2015-06-30 -0.09 0.08
2014-06-30 -0.09 0.10
2013-06-30 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Race Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Race Oncology has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Race Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Race Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Race Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Race Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Race Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Race Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Race Oncology has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Race Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Race Oncology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Race Oncology Company Filings, last reported 7 months ago.

ASX:RAC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.43 0.00 2.08
2018-09-30 6.43 0.00 2.08
2018-06-30 7.93 0.00 3.71
2018-03-31 7.93 0.00 3.71
2017-12-31 5.81 0.00 1.63
2017-09-30 5.81 0.00 1.63
2017-06-30 5.64 0.00 1.70
2017-03-31 5.64 0.00 1.70
2016-12-31 7.29 0.00 3.05
2016-09-30 7.29 0.00 3.05
2016-06-30 4.08 0.01 4.35
2016-03-31 4.08 0.01 4.35
2015-12-31 -0.10 0.00 0.00
2015-09-30 -0.10 0.00 0.00
2015-06-30 0.01 0.00 0.02
2014-06-30 -0.07 0.00 0.05
2013-06-30 0.02 0.00 0.10
  • Race Oncology has no debt.
  • Race Oncology currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Race Oncology has less than a year of cash runway based on current free cash flow.
  • Race Oncology has less than a year of cash runway if free cash flow continues to grow at historical rates of 63.1% each year.
X
Financial health checks
We assess Race Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Race Oncology has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Race Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Race Oncology dividends.
If you bought A$2,000 of Race Oncology shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Race Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Race Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:RAC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
Australia Market Average Dividend Yield Market Cap Weighted Average of 412 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.7%
Australia Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:RAC Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Race Oncology has not reported any payouts.
  • Unable to verify if Race Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Race Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Race Oncology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Race Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Race Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Race Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Race Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Molloy
COMPENSATION A$447,882
AGE 65
TENURE AS CEO 3.1 years
CEO Bio

Mr. Peter Laurence Molloy, BSc, MBA, FAICD has been Managing Director and Chief Executive Officer of Race Oncology Ltd since July 8, 2017. Mr. Molloy served as the Managing Director, President and Chief Executive Officer of Florigene Ltd., where he managed numerous R&D programs, raised equity funding and executed four pharmaceutical partnerships. He served as Managing Director and Chief Executive Officer of Aviragen Therapeutics, Inc. (alternative name Biota Holdings Ltd.) from July 15, 2002 to December 2005. He has 18 years experience in licensing, clinical development and launch of pharmaceutical products in Australia. Mr. Molloy is a US-based Australian executive, with extensive management and commercial experience in the international pharmaceutical and biotechnology arenas. He served as President and Chief Executive Officer of SLIL Biomedical Corp.; and President of Moleculon Inc. In addition, he has seventeen years experience in the international pharmaceutical industry, where he held senior roles with Faulding Healthcare in Australia. He served as the Managing Director of Pharmacia operations in Australia and New Zealand and Vice President of Strategic Marketing for Pharmacia in the US. He has extensive experience in building biotech-pharmaceutical partnerships, raising VC and strategic equity for small biotech companies and Managing Emerging Biotech Businesses. During his career, he has run 7 biotechnology or pharmaceutical businesses, launched 23 pharmaceutical products and executed 40 international licensing or distribution deals. He has been a Director of Race Oncology Ltd since July 08, 2016. He served as Independent Director at Parnell Pharmaceuticals Holdings Ltd. since 2011 until September 8, 2014. He served as a Non-Executive Director of Viralytics Limited since January 31, 2013 until September 08, 2014, Executive Director from July 24, 2012 to January 31, 2013 and served as its Director since September 29, 2008 to July 24, 2012. He served as a Director of Biota Holdings Ltd. until December 9, 2005. He is also a Fellow of the Australian Institute of Company Directors. He is a graduate of Sydney University with an Honours degree in Pharmacy, Master of Science and Doctor of Philosophy (pharmacology and pharmaceutical chemistry) degrees. He holds BS in Biochemistry and Microbiology from The University of Melbourne and MBA from The University of Adelaide.

CEO Compensation
  • Peter's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Peter's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Race Oncology management team in years:

3
Average Tenure
  • The tenure for the Race Oncology management team is about average.
Management Team

Peter Molloy

TITLE
MD, CEO & Director
COMPENSATION
A$448K
AGE
65
TENURE
3.1 yrs

Gordon Beck

TITLE
Senior Vice President of Business Development
COMPENSATION
A$375K
TENURE
3 yrs

Samar Al-Behaisi

TITLE
Chief Medical Officer & VP of Medical Affairs
COMPENSATION
A$276K
TENURE
1.3 yrs

Peter Webse

TITLE
Company Secretary
AGE
56
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure of the Race Oncology board of directors in years:

3.1
Average Tenure
  • The tenure for the Race Oncology board of directors is about average.
Board of Directors

Bill Garner

TITLE
Non Executive Chairman
COMPENSATION
A$118K
AGE
53
TENURE
3.1 yrs

Peter Molloy

TITLE
MD, CEO & Director
COMPENSATION
A$448K
AGE
65
TENURE
3.1 yrs

Chris Ntoumenopoulos

TITLE
Non-Executive Director
COMPENSATION
A$301K
TENURE
3.3 yrs

Martin Tallman

TITLE
Member of Scientific Advisory Board
TENURE
2.7 yrs

Douglas Smith

TITLE
Member of Scientific Advisory Board

Roland Walter

TITLE
Member of Scientific Advisory Board

John Cullity

TITLE
Non-Executive Director
COMPENSATION
A$11K
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
12. Nov 18 Buy William Garner Individual 09. Nov 18 09. Nov 18 350,000 A$0.14 A$47,262
29. Aug 18 Buy William Garner Individual 28. Aug 18 28. Aug 18 50,000 A$0.14 A$7,185
27. Aug 18 Buy Peter Molloy Individual 27. Aug 18 27. Aug 18 45,000 A$0.14 A$6,374
X
Management checks
We assess Race Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Race Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Race Oncology (ASX:RAC) Share Price Is Down 82% So Some Shareholders Are Rather Upset

So take a moment to sympathize with the long term shareholders of Race Oncology Limited (ASX:RAC), who have seen the share price tank a massive 82% over a three year period. … Check out our latest analysis for Race Oncology We don't think Race Oncology's revenue of AU$228,501 is enough to establish significant demand. … A Different Perspective Over the last year, Race Oncology shareholders took a loss of 73%.

Simply Wall St -

What Kind Of Investor Owns Most Of Race Oncology Limited (ASX:RAC)?

A look at the shareholders of Race Oncology Limited (ASX:RAC) can tell us which group is most powerful. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Race Oncology is a smaller company with a market capitalization of AU$5.3m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

How Does Investing In Race Oncology Limited (ASX:RAC) Impact The Volatility Of Your Portfolio?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Do Insiders Own Shares In Race Oncology Limited (ASX:RAC)?

A look at the shareholders of Race Oncology Limited (ASX:RAC) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Race Oncology is a smaller company with a market capitalization of AU$7.2m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

How Does Race Oncology Limited (ASX:RAC) Affect Your Portfolio Volatility?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What You Must Know About Race Oncology Limited's (ASX:RAC) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is RAC right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Are Race Oncology Limited's (ASX:RAC) Interest Costs Too High?

Race Oncology Limited (ASX:RAC), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is RAC will have to follow strict debt obligations which will reduce its financial flexibility. … Is RAC growing fast enough to value financial flexibility over lower cost of capital

Simply Wall St -

Who Are The Major Shareholders In Race Oncology Limited (ASX:RAC)?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, investors should dig deeper into RAC's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in RAC is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Is Race Oncology Limited (ASX:RAC) A Good Healthcare Bet?

As the company trails the rest of the industry in terms of growth, RAC may also be a cheaper stock relative to its peers. … If your initial investment thesis is around the growth prospects of RAC, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Company Info

Description

Race Oncology Limited operates as a specialty pharmaceutical company in Australia. It develops Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Melbourne, Australia.

Details
Name: Race Oncology Limited
RAC
Exchange: ASX
Founded: 1993
A$5,670,327
87,235,813
Website: http://www.raceoncology.com
Address: Race Oncology Limited
140 William Street,
Level 40,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX RAC Common Shares Australian Securities Exchange AU AUD 13. Jul 2016
CHIA RAC Common Shares Chi-X Australia AU AUD 13. Jul 2016
Number of employees
Current staff
Staff numbers
0
Race Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/17 10:38
End of day share price update: 2019/08/13 00:00
Last estimates confirmation: 2018/08/21
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.